Prostanoids, which consist of prostaglandins (PGs) and thromboxanes (TXs), are derived from arachidonic acid via oxidative metabolism induced by cyclooxygenases. Once prostanoids are produced, they act on G-protein-coupled receptors in the tissues they were synthesized. Each of these receptors has been cloned, expressed, and characterized. Coleman et al. proposed that there are receptors specific for PGE, PGF, PGI, PGD, and TX, which were classified into EP, FP, IP, DP and TP receptors, respectively. 1) They further classified the EP receptors into four subtypes (EP1, EP2, EP3 and EP4), all of which respond to PGE 2 in different ways. Characterization of these receptors at the molecular level has resulted in renewed interest in this field. As such, a number of ligands selective for each of these EP subtype receptors have been studied as potential therapeutics.
Prostanoids, which consist of prostaglandins (PGs) and thromboxanes (TXs), are derived from arachidonic acid via oxidative metabolism induced by cyclooxygenases. Once prostanoids are produced, they act on G-protein-coupled receptors in the tissues they were synthesized. Each of these receptors has been cloned, expressed, and characterized. Coleman et al. proposed that there are receptors specific for PGE, PGF, PGI, PGD, and TX, which were classified into EP, FP, IP, DP and TP receptors, respectively. 1) They further classified the EP receptors into four subtypes (EP1, EP2, EP3 and EP4), all of which respond to PGE 2 in different ways. Characterization of these receptors at the molecular level has resulted in renewed interest in this field. As such, a number of ligands selective for each of these EP subtype receptors have been studied as potential therapeutics.
Stimulation of the EP4 receptor with PGE 2 leads to an increase in intracellular cyclic adenosine monophosphate (cAMP) levels, which has been suggested to be coordinated with the cytoprotective effects of PGE 2 , such as protection of organs and/or tissue from damage. Highly potent EP4 subtype-selective receptor agonists have been suggested to have therapeutic potential without side effects, such as uterine contractions, which are considered to be mediated by the EP3 subtype. Previously, we discovered 5-thiaPGE 1 1 (Fig.  1) , a highly potent EP4 subtype selective agonist, which suppresses the lipopolysaccharide (LPS)-induced production of tumor necrosis factor (TNF)-a following its intravenous (i.v.) infusion.
2) However, 1 demonstrated a poor pharmacokinetic (PK) profile (i.e. bioavailability Ͻ1%), which was estimated to be mainly due to its metabolic instability and/or low membrane permeability (i.e. Caco-2 permeability of 1: Ͻ10 Ϫ7 cm/s). Thus, the development of a structurally novel and orally available EP4 subtype-selective agonist has been warranted to serve as an orally available drug candidate. Several research groups have been investigating g-lactam PGE analogs for the purpose of improving their chemical and metabolic stability. [3] [4] [5] [6] In a previous report, 7) we identified glactam PGE analogs 2a and 3a ( Fig. 1) , as novel chemical leads for a class of chemically and metabolically stable EP4 receptor agonists, which have a w-chain moiety 16-(3-methoxymethyl)phenyl, based on previously reported data on cyclopentane PGE analogs. 2, 7) To further optimize these compounds and potentially identify an orally available EP4 subtype selective agonist, we wanted to focus on chemically modifying the 16-phenyl moiety of 2a and 3a. Thus, an investigation on the optimal w-chain moiety of the new g-lactam scaffolds was conducted. Herein, we report on the discovery of more optimized EP4 receptor agonists, 3b, c and 3k, derived from the chemical leads 2a and 3a. The structure-activity relationships (SARs) of these novel analogs are presented.
Chemistry The synthesis of compounds 2a and 3a was reported in our previous paper.
7 ) The synthesis of test compounds listed in Table 1 is outlined in Charts 1a-e and 2a, b. Compounds 2b-j, 3b, 3d-i and 3j were synthesized as described in Chart 1a. 1-N-Alkyl 5-hydroxymethylpyrrolidin-2-ones 4a, b 7) were oxidized with a sulfur trioxide-pyridine complex in dimethyl sulfoxide (DMSO) and the presence of diisopropylethylamine to yield the corresponding aldehydes 5a, b, respectively. Horner-Emmons olefination of 5a, b using an optional phosphonate of 10a-j yielded 6a-c and 7a-h, respectively. A stereoselective reduction of these compounds with (R)-Me-CBS and borane-tetrahydrofuran (THF) complex yielded 8a-i and 9a-h, respectively. Alkaline hydrolysis of 8a-i and 9a-h resulted in 2b-j, 3b, 3d-i and 3j, respectively.
Phosphonates 10a-l were prepared as outlined in Charts 1b-e. As shown in Chart 1b, commercially available phenylacetic acids were converted into corresponding Weinreb amides 18a-c, 18e, 18h, i and 18j, respectively, via peptide synthesis. They were then converted into phosphonates 10a-c, 10e, 10h, i and 10j, respectively, using a conventional procedure.
As shown in Chart 1c, phosphonates 10d and 10k were prepared from their corresponding phenylacetic acids using the same procedures described above. Esterification of a commercially available (m-bromophenyl)acetic acid followed by a treatment with alkenyl(tributyl)tin in the presence of tetrakis-triphenylphosphine palladium yielded methyl (malkenylphenyl)acetates 19a, b. A catalytic hydrogenation of these compounds yielded methyl (m-alkylphenyl)acetates 20a, b, respectively. Alkaline hydrolysis of 20a, b, similar to that described above, resulted in 10d and 10k, respectively.
Phosphonates 10f, g were prepared as shown in Chart 1d. Monosubstitution of the commercially available 1,3-bis(bromophenyl)benzene with sodium 2,2,2-trifluoroethoxide, followed by a palladium-catalyzed carbonyl insertion reaction in the presence of potassium carbonate and methanol yielded 21, which was then converted into phosphonate 10f, based on the same procedure described above. Monosubstitution of 1,3-bis(bromomethyl)benzene with potassium acetate, followed by a palladium-catalyzed carbonyl insertion reaction in the presence of potassium carbonate and methanol yielded 22. A palladium-catalyzed vinylation of 22 with ethylvinyl ether in the presence of palladium diacetate and 1,10-phenanthroline yielded 23. 8) Simmons-Smith reaction of 23 with diiodomethane and diethylzinc yeilded 24. Based on the same procedure described above, 24 was converted into 10g.
Phosphonate 10l was prepared as shown in Chart 1e. OProtection of the commercially available 4-butyn-1-ol as a tetrahydropyranyl ether, followed by ethoxycarbonylation with ethyl chloroformate in the presence of n-butyllithium yielded 25. An acidic deprotection 25 yielded 26. Swern oxidation of 26, followed by methylation of the produced aldehyde with a methyl Grignard reagent yielded 27, and a repeated Swern oxidation of 27 resulted in a methyl ketone 28. Treatment of 28 with sodium hydride in N,N-dimethylformamide yielded (5-methyl)furan-2-yl acetic acid 29, 9) which was then converted into 10l, similarly as described above.
The synthesis of 3c and k is described in Chart 2a. Alcoholysis followed by an S-alkylation of 1-N-alkyl 5-tert-butyldimethylsilyloxymethylpyrrolidin-2-one 11 with an iodide 17, as described in Chart 2b, yielded 12, and deprotection of 12 with tetra-butylammonium fluoride (TBAF) yielded 13. Oxidation of 13 produced an aldehyde 14, which was easier to extract with an organic solvent, as it is more hydrophobic than the above mentioned corresponding methyl and ethyl esters 5a, b. A Horner-Emmons olefination of 14 with phosphonates 10k, l yielded enones 15a, b, respectively, and stereoselective reduction of enones 15a, b with (R)-Me-CBS and borane-THF complex resulted in the desired diastereoisomers 16a, b, respectively. Alkaline hydrolysis of 16a, b yielded carboxylic acids 3c and 3k, respectively.
Results and Discussion
The compounds listed in Table 1 were evaluated for their binding affinity for mouse EP receptor subtypes. The agonist activities of these compounds on each of the EP4 receptor subtype were also evaluated.
Results are summarized in Table 1 . Design and synthesis of 16-(2-methyl)phenyl, 16-(3-methyl)phenyl and 16-(4-methyl)phenyl analogs resulted in 2b-d, respectively, with good to excellent EP4 subtype selectivity. Among the tested isomers, meta-isomer 2c demonstrated the most potent receptor affinity and agonist activity for EP4 subtype, while 5-thia analog 3b demonstrated equipotent receptor affinity and agonist activity with 2c. para-Isomer 2d demonstrated a 41-fold less potent EP4 affinity in comparison to 2c, while ortho-isomer 2b demonstrated a 94-fold less potent affinity. As a result, ortho-and para-substitution of the 16-phenyl moiety appears to be deleterious in EP4 receptor affinity. Based on these findings, more analogs, specifically 2e, f, which possess a 16-(3-substituted)phenyl moiety, were synthesized and evaluated. Both analogs exhibited very potent affinity and subtype-selectivity for EP4 receptor, however there was a significant reduction in their agonist activity for their very potent receptor affinity. Meanwhile, 16-(3-alkyl)phenyl 5-thia analogs 3c, d demonstrated very potent activity in both receptor affinity and agonist activity. A reduction in the agonist activity of 3c, d was much lower compared with 5-methylene analogs 2e, f, respectively. Furthermore, 5-thia analogs 3b-d appeared to have more potent agonist activities than 5-methylene analogs 2c and 2e, f, respectively, while their EP4 receptor affinity did not differ between the two series of analogs. Similar SARs were also observed between 2g, h and 3e, f. Thus, an introduction of a 5-thia moiety appears to be effective in preventing a reduction in agonist activity due to presumed potential increase in the lipophilicity and/or bulkiness of the meta-substituent, as illustrated by the SARs of 2c, 2e-h and 3b-f.
Interestingly, 5-thia-16-(3-fluoro)phenyl and 5-thia-16-(3-chloro)phenyl analogs 3h, i, and 5-methylene analogs 2i, j demonstrated completely opposite SARs, respectively, as shown in Table 1 . The reason why the 5-thia-16-(3-fluoro)-phenyl analog 3h exhibited reduced agonist activity relative to the corresponding 5-methylene analog 2i is still not clear while the decreased agonist activity of 5-thia-16-(3-chloro)-phenyl analog 3i relative to that of the corresponding 5-methylene analog 2j seemed to be due to the decreased EP4 receptor affinity of 3i relative to 2j. Thus, 16-(3-fluoro)phenyl analogs 2i and 3h may have different SARs from 16-(3-alkyl)phenyl analogs.
The synthesis and evaluation of an 16-(3-cyclopropyloxymethyl)phenyl 5-thia analog 3g resulted in the equipotency and subtype-selectivity that were similar to its structurally-related compounds 3a and 3f. The effects of replacing the terminal 16-phenyl moiety in the more optimized 5-thia analogs with five-membered heterocyclic rings, such as thiophene and furan, on their activity profiles were also investigated. Replacement of the 16-phenyl moiety with 16-(thiophen-2-yl) and 16-(5-methylfuran-2-yl) moieties in these 5-thia analogs yielded 3j and k, respectively. Both analogs demonstrated very potent EP4 receptor affinity with good agonist activity. In particular, 3k exhibited the most potent agonist activity of all tested analogs.
Of the compounds tested, analogs 3b and 3c demonstrated improved PK profiles (C max and AUC) and bioavailability compared with 2a ( Table 2 ). The membrane permeability of 3b, c may, in part, improve their lipophilicity, and thereby their PK profiles and bioavailability. Conversely, the poor PK profile of 3k may be a result of its relatively lower C max and oral exposure (AUC), which may be due to its poor membrane permeability, as it has greater hydrophilicity. Furthermore, given that 3b, c and 3k were metabolically stable in rat liver microsomes (RLM) and human liver microsomes (HLM), these analogs may have been cleared through other metabolic pathways, such as b-oxidation, conjugation or excretion.Since our objective was to discover an orally available EP4 subtype selective agonist, we evaluated the biological properties of the developed compounds in an in vivo inhibition assay for LPS-induced TNF-a production in rats (Table 3) . Additionally, prior to assessing the in vivo efficacy of EP4 subtype-selective agonists 2a, 3b, c, and 3k, their pharmacokinetic profiles and intracellular cAMP production were evaluated in rat Chinese hamster ovary (CHO) cells expressing EP4-receptors. The results from these experiments are summarized in Table 3 .
Lastly, 2a demonstrated an ED 50 at ca. 1000 mg/kg per os ( p.o.), while 3b, c, and 3k demonstrated relatively higher in vivo potencies. Thus, an introduction of a sulfur atom in the 5-position, followed by chemical modification of the 16-phenyl moiety, resulted in enhanced in vivo efficacy. In particular, analog 3k demonstrated a more potent in vivo efficacy (ED 50 : 30 mg/kg, p.o.) compared with 2a and 3b, c. The significantly more potent functional activity of 3k compared with other analogs was considered to be one of the plausible reasons of its higher in vivo efficacy.
Conclusion
In conclusion, a series of 8-aza-16-arylPGE 1 and 8-aza-5-thia-16-arylPGE 1 analogs were synthesized and investigated for their subtype receptor affinity and EP4 agonist activity. 16-(meta-Alkyl)phenyl analogs demonstrated excellent EP4 subtype-selectivity via binding assays. The discovery of 3b, c and 3k, which showed more improved bioavailability and/or in vivo efficacy compared with 2a, was presented. Additionally, we found interesting SARs between two series of analogs, 5-methylene and 5-thia.
Based on our findings, the newly discovered subtypeselective EP4 agonists could have potential therapeutic benefits for the treatment of diseases, such as rheumatoid arthritis, inflammatory bowel disease, Crohn's disease and psoriasis, in which plasma TNF-a level are higher than normal.
Experimental
Analytical samples were homogeneous as confirmed by TLC, and afforded spectroscopic results consistent with the assigned structures. Proton nuclear magnetic resonance spectra ( 6 mmol) and triethylamine (5.6 ml, 40.0 mmol) in CH 3 CN (15 ml) was added a solution of (2-methylphenyl)acetic acid (4.00 g, 26.6 mmol) in CH 3 CN (17 ml) at room temperature under argon atmosphere. After being stirred for 1 h, the reaction was quenched with water. The reaction mixture was diluted with EtOAc, washed with 2 N HCl, water, then brine, and dried over MgSO 4 . The organic solvent was removed by evaporation to give a Weinreb amide 18a as a colorless oil. 
3-(2-Methylphenyl)-2-oxopropanephosphonate (10a)
To a stirred solution of dimethyl methylphosphonate (4.0 ml, 37.3 mmol) in toluene (80 ml) was added dropwise a solution of n-BuLi (1.57 M in hexane, 37.3 mmol) at Ϫ78°C under argon atmosphere, and stirring was continued for 1 h at the same temperature. To the reaction mixture was added a solution of 18a (26.6 mmol) in toluene (50 ml), and stirring was continued for additional 2 h at the same temperature. The reaction was quenched with acetic acid. The reaction mixture was allowed to warm up to room temperature with stirring. The reaction mixture was diluted with EtOAc, washed with water, then brine, and dried over MgSO 4 . The solvent was removed by evaporation and the resulting residue was purified by column chromatography on silica gel (hexane/EtOAc, 3/2-0/1) to give a phosphonate 10a as a pale yellow oil (4.19 g, 61% in 2 steps). 
Ethyl 7-[(2R)-2-{(1E,3S)-3-Hydroxy-4-[2-methylphenyl]-1-buten-1-yl}-5-oxo-1-pyrrolidinyl]heptanoate (8a)
To a stirred solution of the alcohol 4a (400 mg, 1.47 mmol) in EtOAc (3.5 ml) and diisopropylethylamine (1.5 ml, 8.84 mmol) was added a solution of SO 3 -Py (704 mg, 4.42 mmol) in DMSO (2.5 ml) at 0°C under argon atmosphere. After being stirred at the same temperature for 20 min, the reaction was quenched with 1 N HCl. The reaction mixture was exracted with EtOAc three times, washed with saturated aqueous NaHCO 3 , brine, and dried over MgSO 4 . The organic solvent was removed by evaporation to yield an aldehyde 5a as a pale yellow oil.
To a stirred solution of dimethyl 3-[(3-methylphenyl]-2-oxopropanephosphonate 10a (264 mg, 1.03 mmol) in THF (10 ml) was added sodium hydride (63% in mineral oil, 35.0 mg, 0.884 mmol) in several portions at 0°C under argon atmosphere. After being stirred at ambient temperature for 90 min, to this stirred suspension was added a solution of the above-described aldehyde 5a in THF (1 ml) at 0°C and stirring was continued for 2 h. The reaction mixture was quenched with acetic acid. The resulting solution was diluted with EtOAc, washed with water, then brine, and dried over MgSO 4 . The solvent was removed by evaporation to give an enone 6a as a pale yellow oil.
To a stirred solution of 6a in THF (4.0 ml) was added a solution of (R)-2-methyl-CBS-oxazaborolidine (1.0 M in toluene, 0.184 ml, 0.184 mmol) at room temperature under argon atmosphere. To this reaction mixture was added dropwise a solution of borane-THF complex (1.0 M in THF, 0.44 ml, 0.442 mmol) in 5 min. The resulting solution was stirred for 1 h, then treated with MeOH (0.3 ml) and stirring was continued for 5 min. The reaction mixture was diluted with EtOAc, washed with 1 N HCl, water, saturated NaHCO 3 , brine, and dried over Na 2 SO 4 . The solvent was removed by evaporation, and the resulting residue was purified by column chromatography on Vol. 59, No. 12 
7-{(2R)-2-[(1E,3S)-3-Hydroxy-4-(2-methylphenyl)but-1-enyl]-5-oxopyrrolidin-1-yl}heptanoic Acid (2b)
A solution of 8a (130 mg, 0.324 mmol) in EtOH (0.3 ml), DME (0.1 ml) and 2 N NaOH (0.39 ml) was stirred at ambient temperature for 10 h. After neutralization with 2 N HCl (0.4 ml) under cooling, the reaction mixture was extracted with EtOAc three times, and the organic layer was washed with brine, dried over Na 2 SO 4 . The organic solvent was removed by evaporation. The resulting residue was purified by column chromatography on silica gel (CHCl 3 /MeOH, 50/1-20/1) to afford 2b as a colorless oil (99 mg, 82% 
Ethyl 7-{(2R)-2-[(1E,3S)-3-Hydroxy-4-(3-methylphenyl)-1-buten-1-yl]-5-oxo-1-pyrrolidinyl}heptanoate (8b)
Compound 8b was prepared from 5a using 10b instead of 10a according to the same procedure as described of 8a from 5a as a pale yellow oil (yield 56% in 3 steps). 
Methyl 4-{(2-{(2R)-2-[(1E)-4-(3-Methylphenyl)-3-oxo-1-buten-1-yl]-5-oxo-1-pyrrolidinyl}ethyl)thio}butanoate (9a)
Compound 9a was prepared from 5b using 10b instead of 10a according to the same procedure as described of 8a from 5a as a pale yellow oil (227 mg, 49% in 3 steps). 
4-[(2-{(2R)-2-[(1E,3S)-3-Hydroxy-4-(3-methylphenyl)but-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)sulfanyl]butanoic Acid (3b)
Compound 3b was prepared from 9a according to the same procedure as described of 2b from 8a as a pale yellow oil (yield 99% 74 (s, 2H), 3.61 (s, 3H), 3.18 (s, 3H), 2.36 (s, 3H) .
3-(4-Methylphenyl)-2-oxopropanephosphonate (10c) Compound 10c
was prepared from 18c according to the same procedure as described of 10a from 18a as a pale yellow oil (yield 70% in 2 steps (3-Vinylphenyl)acetate (19a) To a stirred solution of (3-bromophenyl)-acetic acid (10.0 g, 46.5 mmol) and potassium carbonate (19.3 g, 140 mmol) in DMF (200 ml) was added methyl iodide (8.7 ml, 140 mmol) at room temperature under argon atmosphere. After being stirred at room temperature for 12 h, the reaction mixture was diluted with EtOAc (50 ml) and hexane (100 ml), washed with H 2 O twice, brine, and dried over MgSO 4 . The organic solvent was removed by evaporation and the resulting residue was purified by column chromatography on silica gel (hexane/EtOAc, 5/1) to give an ester as a colorless oil (9.14 g, 86%). To a stirred solution of above-described ester (5.0 g, 21.8 mmol) in toluene (40 ml) were added vinyltributyltin (6.7 ml, 22.9 mmol) and tetrakis(triphenylphosphine)palladium (504 mg, 0.44 mmol) at under argon atmosphere. After being stirred at 110°C for 2 h, the reaction mixture was cooled to room temperature. The resulting mixture was filtered through a pad of Celite, and the filtrate was evaporated and purified by column chromatography on silica gel (hexane/EtOAc, 20/1-5/1) to afford 19a as a colorless oil (3.17 g, 82%). 67 mmol) in MeOH (10 ml) was vigorously stirred under hydrogen atmosphere in the presence of palladium on carbon (100 mg) for 1 h. The catalyst was removed by filtration. The filtrate was evaporated and purified by column chromatography on silica gel (hexane/EtOAc, 4/1) to afford 20a as a colorless oil (890 mg, 88%). 3-(3-Ethylphenyl)-2-oxopropanephosphonate (10k) A solution of 20a (890 mg, 5.0 mmol) in MeOH (4.0 ml) and 2 N NaOH (3.0 ml, 6.0 mmol) was stirred at room temperature for 1 h. After neutralization with 2 N HCl under cooling, the reaction mixture was extracted with EtOAc three times, and the organic layer was washed with brine, dried over MgSO 4 . The organic solvent was removed by evaporation to afford a carboxylic acid as a white powder (855 mg, 100% Compound 10k was prepared from above-described carboxylic acid according to the same procedure as described of 10a from (2-methylphenyl)acetic acid as a colorless oil (yield 70% in 2 steps). Compound 8d was prepared from 5a using 10k instead of 10a according to the same procedure as described of 8a from 5a as a colorless oil (yield 55% in 3 steps). , 2H), 4.05 (m, 1H), 3.49 (m, 1H), 2.90-2.78 (m, 2H) 
7-{(2R)-2-[(1E,3S)-3-Hydroxy-4-(3-ethylphenyl)-1-buten-1-yl]-5-oxo-1-pyrrolidinyl}heptanoate (2e)
Compound 2e was prepared from 8d according to the same procedure as described of 2b from 8a as a colorless oil(75 mg, yield 98% 
Ethyl 7-{(2R)-2-[(1E,3S)-3-Hydroxy-4-(3-propylphenyl)-1-buten-1-yl]-5-oxo-1-pyrrolidinyl}heptanoate (8e)
Compound 8e was prepared from 5a using 10d instead of 10a according to the same procedure as described of 8a from 5a as a colorless oil (255 mg, yield 48% in 3 steps). 
7-{(2R)-2-[(1E,3S)-3-Hydroxy-4-(3-propylphenyl)-1-buten-1-yl]-5-oxo-1-pyrrolidinyl}heptanoate (2f)
Compound 2f was prepared from 8e according to the same procedure as described of 2b from 8a as a colorless oil (47 mg, yield 96% 
Methyl 4-{(2-{(2R)-2-[(1E)-4-(3-Propylphenyl)-3-oxo-1-buten-1-yl]-5-oxo-1-pyrrolidinyl}ethyl)thio}butanoate (9b)
Compound 9b was prepared from 5b using 10d instead of 10a according to the same procedure as described of 8a from 5a as a colorless oil (155 mg, 49% in 3 steps). 
4-[(2-{(2R)-2-[(1E,3S)-3-Hydroxy-4-(3-propylphenyl)but-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)sulfanyl]butanoic Acid (3d)
Compound 3d was prepared from 9b according to the same procedure as described of 2b from 8a as a pale yellow oil (yield 99% 
N-Methoxy-N-methyl-2-[3-(trifluoromethyl)phenyl]acetamide (18e)
Compound 18e was prepared from 3-(trifluoromethyl)phenylacetic acid according to the same procedure as described of 18a from (2-methylphenyl)acetic acid as a yellow oil.
3-[3-(Trifluoromethyl)phenyl]-2-oxopropanephosphonate (10e)
Compound 10e was prepared from 18e according to the same procedure as described of 10a from 18a as a colorless oil (yield 57% in 2 steps). 
Ethyl 7-[(2R)-2-{(1E,3S)-3-Hydroxy-4-[3-(trifluoromethyl)phenyl]-1-buten-1-yl]}-5-oxo-1-pyrrolidinyl]heptanoate (8f)
Compound 8f was prepared from 5a using 10e instead of 10a according to the same procedure as described of 8a from 5a as a pale yellow oil (yield 52% in 3 steps 
7-((2R)-2-{(1E,3S)-3-Hydroxy-4-[3-(trifluoromethyl)phenyl]-1-buten-1-yl}-5-oxo-1-pyrrolidinyl)heptanoate (2g)
Compound 2g was prepared from 8f according to the same procedure as described of 2b from 8a as a white powder (yield 83% 
Methyl 4-{(2-{(2R)-2-[(1E)-4-(3-Trifluoromethylphenyl)-3-oxo-1-buten-1-yl]-5-oxo-1-pyrrolidinyl}ethyl)thio}butanoate (9c)
Compound 9c was prepared from 5b using 10e instead of 10a according to the same procedure as described of 8a from 5a as a colorless oil (90 mg, 30% in 3 steps). in THF (10 ml). After being stirred for additional 4 h, the reaction mixture was poured into ice-cold aqueous NH 4 Cl, extracted with EtOAc, washed with H 2 O, brine, and dried over MgSO 4 . The organic solvent was removed by evaporation to give an ether. To a stirred solution of the above-described ether in THF (30 ml) and MeOH (15 ml) were added potassium carbonate (5.0 g, 36.0 mmol) and bis(triphenylphosphine)palladium dichloride (280 mg, 0.40 mmol) under argon atmosphere, and the reaction vessel was replaced with CO gas repeatedly. After being stirred at room temperature for 3 h, the resulting mixture was diluted with EtOAc and filtered through a pad of Celite. The filtrate was evaporated and purified by column chromatography on silica gel (hexane/EtOAc, 9/1) to afford 21 as a brown oil (3.28 g, 63%).
3-[3-(2,2,2-Trifluoroethoxymethyl)phenyl]-2-oxopropanephosphonate (10f)
Compound 10f was prepared from 21 according to the same procedure as described of 10d from 20a as a colorless oil (2.28 g, yield 52% in 3 steps). 1 
Ethyl 7-[(2R)-2-{(1E,3S)-3-Hydroxy-4-[3-(2,2,2-trifluoroethoxymethyl)phenyl]-1-buten-1-yl]}-5-oxo-1-pyrrolidinyl]heptanoate (8g)
Compound 8g was prepared from 5a using 10f instead of 10a according to the same procedure as described of 8a from 5a as a colorless oil (61 mg, yield 17% in 3 steps). 35 (m, 1H), 3.00-1.80 (m, 6H), 2.33 (t, Jϭ7.0 Hz, 2H), 1.80-1.55 (m,  3H) 2-{(2R)-2-[(1E)-4-(3-(2,2,2-Trifluoroethoxymethyl)  phenyl)-3-oxo-1-buten-1-yl]-5-oxo-1-pyrrolidinyl}ethyl) thio}butanoate (9d) Compound 9d was prepared from 5b using 10f instead of 10a according to the same procedure as described of 8a from 5a as a colorless oil (112 mg, 41% in 3 steps). 39 (m, 1H), 4.16-4.07 (m, 1H), 3.84 (q, Jϭ9.0 Hz, 2H), 3.68 (s,  3H), 3.68-3.56 (m, 1H), 3.03-2.92 (m, 1H), 2.92-2.80 (m, 2H), 2.69-2.48 (m, 4H), 2.48-2.33 (m, 4H), 2.33-2.16 (m, 1H), 1.95-1.85 (m, 3H),  1.79-1.63 (m, 1H) . 2-[(1E,3S)-3-Hydroxy-4-(3-(2,2,2-trifluoroethoxymethyl)-phenyl)but-1-enyl]-5-oxopyrrolidin-1-yl}ethyl) 0 mmol) at room temperature under argon atmosphere After being stirred at 60°C for 3 h, the resulting solution was cooled to ambient temperature, and diluted with EtOAc/hexane, washed with water, dried over MgSO 4 . The organic solvent was removed by evaporation to afford a monobromide as brown oil. To a stirred solution of above-described monobromide in MeOH (15 ml) and THF (30 ml) were added potassium carbonate (5.00 g, 36.2 mmol) and bis(triphenylphosphine)palladium dichloride (280 mg, 0.40 mmol) under argon atmosphere, and the reaction vessel was replaced with CO gas repeatedly. After being stirred at room temperature for 6 h, the resulting mixture was evaporated and purified by column chromatography on silica gel (hexane/EtOAc, 2/1-1/1) to afford 22 as a dark brown oil (1.68 g, 48% in 2 steps). 68 g, 9 .30 mmol), ethyl vinyl ether (20 ml), 1,10-phenanthroline (85 mg, 0.47 mmol) in CH 2 Cl 2 (5 ml) was added palladium acetate (106 mg, 0.47 mmol) at room temperature under argon atmosphere. After being stirred for 2 d, the resulting mixture was evaporated and purified by column chromatography on silica gel (hexane/EtOAc, 9/1) to afford 23 as a pale yellow oil (1.35 g, 70%). 35 g, 6 .60 mmol) in diethyl ether (30 ml) were successively added a solution of diethylzinc (1.0 M in hexane, 13.0 ml, 13.0 mmol) and a solution of diiodomethane (3.75 g, 14 mmol) in diethyl ether (10 ml) at room temperature under argon atmosphere. Stirring was continued at 35°C for 8 h and the reaction mixture was poured into 1 N HCl, extracted with diethyl ether, washed with brine and dried over Na 2 SO 4 . The solvent was removed by evaporation and the resulting residue was purified by column chromatography on silica gel (hexane/EtOAc, 15/1-10/1) to give 24 as a colorless oil (830 mg, 57%). -1-buten-1-yl]-5-oxo-1-pyrrolidinyl}ethyl) thio]butanoate (9f) Compound 9f was prepared from 5b using 10g instead of 10a according to the same procedure as described of 8a from 5a as a colorless oil (105 mg, yield 42% in 3 steps). , 1H), 3.40-3.32 (m, 1H), 3.02-2.92 (m, 1H), 2.92-2.78 (m, 2H) 3-(3-Fluorophenyl)-2-oxopropanephosphonate (10h) Compound 10h was prepared from 18h according to the same procedure as described of 10a from 18a as a colorless oil (yield 78% in 2 steps). Compound 8h was prepared from 5a using 10h instead of 10a according to the same procedure as described of 8a from 5a as a colorless oil (225 mg, yield 53% in 3 steps). N-Methoxy-N-methyl-2-(3-chlorophenyl]acetamide (18i) Compound 18i was prepared from (3-chlorophenyl)acetic acid according to the same procedure as described of 18a from (2-methylphenyl)acetic acid as a pale yellow oil.
4-[(2-{(2R)-

Methyl 4-[(2-{(2R)-2-[(1E,3S)-3-Hydroxy-4-{3-[(2,2,2-trifluoroethoxy)-methyl]phenyl}
3-(3-Chlorophenyl)-2-oxopropanephosphonate (10i) Compound 10i was prepared from 18i according to the same procedure as described of 10a from 18a as a colorless oil (yield 83% in 2 steps). 7-[(2R)-2-(1E,3S)-3-Hydroxy-4-(3-chlorophenyl]-1-buten-1-yl] }-5-oxo-1-pyrrolidinyl]heptanoate (8i) Compound 8i was prepared from 5a using 10i instead of 10a according to the same procedure as described of 8a from 5a as a colorless oil (56 mg, yield 18% in 3 steps). 1 6-(Tetrahydro-2H-pyran-2-yloxy)-2-hexynoate (25) To a stirred solution of 4-butyn-1-ol (4.21 g, 50.0 mmol) in CH 2 Cl 2 (50 ml) was added 3,4-dihydro-2H-pyran (5.02 ml, 55.0 mmol) and p-toluenesulfonic acid monohydrate (475 mg, 2.50 mmol) at room temperature under argon atmosphere. After being stirred for 10 min, the reaction was treated with triethylamine. The organic solvent was removed by evaporation, and the resulting residue was purified by column chromatography on silica gel (hexane/EtOAc, 4/1) to give an ether as a pale yellow oil (8.01 g, 95%). 60 (m, 1H), 3.85 (m, 2H), 3.50 (m, 2H), 2.31 (m, 2H) To a stirred solution of 25 (8.01 g, 47.6 mmol) in THF (100 ml) was slowly added n-butyllithium (1.56 M in hexane, 33.6 ml, 52.4 mmol) at Ϫ70°C under argon atmosphere and stirring was continued for 1 h at the same temperature. To the reaction mixture was slowly added ethyl chloroformate (13.7 ml, 143 mmol). After being stirred for additional 3 h at room temperature, the reaction mixture was poured into ice-cold aqueous NH 4 Cl, extracted with EtOAc, washed with water, brine, and dried over Na 2 SO 4 . The organic solvent was removed by evaporation, and the resulting residue was purified by column chromatography on silica gel (hexane/EtOAc, 4/1) to give 25 as a colorless oil (11.4 g, 100%) . 6-Hydroxy-2-hexynoate (26) A mixture of 25 (11.4 g, 47.4 mmol) and p-toluenesulfonic acid monohydrate (900 mg, 4.74 mmol) in EtOH (50 ml) was stirred at room temperature for 3 h under argon atmosphere. After quenching with triethylamine, the resulting mixture was evaporated and purified by column chromatography on silica gel (hexane/EtOAc, 1/1) to yield 26 as a colorless oil (5.30 g, 72%). 6-Hydroxy-2-heptynoate (27) To a stirred solution of oxalyl chloride (4.15 ml, 47.6 mmol) in CH 2 Cl 2 (40 ml) was slowly added a solution of DMSO (4.34 ml, 61.2 mmol) in CH 2 Cl 2 (20 ml) at Ϫ70°C in 10 min. The resulting solution was stirred for an additional 15 min at that temperature. To the reaction mixture was added a solution of 26 (5.30 g, 34.0 mmol) in CH 2 Cl 2 (10 ml)in, and the resulting suspension was allowed to warm up to Ϫ35°C in 30 min. After being stirred for an additional 10 min, the reaction mixture was treated with N,N-diisopropylethylamine (16.6 ml, 95.2 mmol) and the resulting suspension was allowed to warm up to Ϫ5°C in 30 min. The reaction was quenched with water and then poured into ice-cold 0.5 N HCl. The mixture was extracted with EtOAc and the organic layer was washed with 1 N HCl, water and brine, and dried over MgSO 4 . The organic solvent was removed by evaporation to give an aldehyde as a pale yellow oil.
To a stirred solution of an above-described aldehyde in THF (70 ml) was added a solution of methylmagnesium bromide (0.93 M in THF, 40.2 ml, 37.4 mmol) at 0°C under argon atmosphere. After being stirred for 15 min, the reaction mixture was poured into 1 N HCl, extracted with EtOAc, washed with brine, and dried over Na 2 SO 4 . The organic layer was evaporated and the resulting mixture was purified by column chromatography on silica gel (hexane/EtOAc, 4/1) to yield 27 as a colorless oil(1.41 g, 24%). 6-Oxo-2-heptynoate (28) To a stirred solution of oxalyl chloride (1.01 ml, 11.6 mmol) in CH 2 Cl 2 (10 ml) was slowly added a solution of DMSO (1.06 ml, 14.9 mmol) in CH 2 Cl 2 (5 ml) at Ϫ70°C in 10 min. The resulting solution was stirred for an additional 15 min at that temperature. To the reaction mixture was added a solution of 27 (1.41 g, 8.29 mmol), and the resulting suspension was allowed to warm up to Ϫ35°C in 30 min. After being stirred for an additional 10 min, the reaction mixture was treated with N,N-diisopropylethylamine (4.04 ml, 23.3 mmol) and the resulting suspension was allowed to warm up to Ϫ5°C in 30 min. The reaction was quenched with water and then poured into ice-cold 0.5 N HCl. The mixture was extracted with EtOAc and the organic layer was washed with 1 N HCl, water and brine, and dried over MgSO 4 . The organic solvent was removed by evaporation to give a methyl ketone 28 as a pale brown oil (794 mg, 57% (5-Methyl-2-furyl)acetate (29) To a stirred solution of 28 (637 mg, 3.79 mmol) in DMF (75 ml) was added sodium hydride (62% in mineral oil, 161 mg, 4.17 mmol) at room temperature under argon atmosphere, and then stirring was continued at 90°C for 3 h. After being cooled to room temperature, the reaction was quenched with saturated aqueous NH 4 Cl. The reaction mixture was extracted with MTBE, washed with H 2 O twice, brine, and dried over MgSO 4 . The organic solvent was removed by evaporation and the resulting residue was purified by column chromatography on silica gel (hexane/EtOAc 1/1) to give an ester 29 as a pale yellow oil (160 mg, 25%). [3-(5-Methyl-2-furyl)-2-oxopropyl]phosphonate (10l) Compound 10l was prepared in the same procedure as described of 10d from 20a as a pale yellow oil (128 mg, yield 53% in 3 steps). 91 (m, 1H), 3.84 (s, 2H), 3.82 (s, 3H), 3.78 (s, 3H) , 3.14 (d,
